These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 6178155)

  • 21. Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease.
    Floyd-Smith G; Slattery E; Lengyel P
    Science; 1981 May; 212(4498):1030-2. PubMed ID: 6165080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-course of actinomycin D inhibition of tobacco mosaic virus multiplication relative to the rate of spread of the infection.
    Dawson WO
    Intervirology; 1978; 9(5):304-9. PubMed ID: 621138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the epidermis in local lesion formation and the multiplication of tobacco mosaic virus and its relation to kinetin.
    Kasamo K; Shimomura T
    Virology; 1977 Jan; 76(1):12-8. PubMed ID: 835224
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of Epstein-Barr virus-associated nuclear antigen (EBNA) induction by (2',5')oligoadenylate and the cordycepin analog: mechanism of action for inhibition of EBV-induced transformation.
    Henderson EE; Doetsch PW; Charubala R; Pfleiderer W; Suhadolnik RJ
    Virology; 1982 Oct; 122(1):198-201. PubMed ID: 6291233
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon action may be mediated by activation of a nuclease by pppA2'p5'A2'p5'A.
    Baglioni C; Minks MA; Maroney PA
    Nature; 1978 Jun; 273(5664):684-7. PubMed ID: 208001
    [No Abstract]   [Full Text] [Related]  

  • 26. Analogue inhibitor of 2-5A action: effect on the interferon-mediated inhibition of encephalomyocarditis virus replication.
    Watling D; Serafinowska HT; Reese CB; Kerr IM
    EMBO J; 1985 Feb; 4(2):431-6. PubMed ID: 2410258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Potent natural inhibitors of tobacco mosaic virus multiplication].
    Martin-Tanguy J; Martin C; Gallet M; Vernoy R
    C R Acad Hebd Seances Acad Sci D; 1976 Jun; 282(24):2231-4. PubMed ID: 822960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [(2'-5') oligoadenylate and its synthetase (author's transl)].
    Sokawa Y
    Seikagaku; 1981; 53(11):1234-8. PubMed ID: 6278031
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-mitogenic function of interferon-induced (2'-5')oligo(adenylate) and growth-related variations in enzymes that synthesize and degrade this oligonucleotide.
    Kimchi A; Shure H; Revel M
    Eur J Biochem; 1981; 114(1):5-10. PubMed ID: 6163628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assay of effect of human interferons on tobacco protoplasts.
    Sela I
    Methods Enzymol; 1986; 119():744-52. PubMed ID: 3762419
    [No Abstract]   [Full Text] [Related]  

  • 31. Production, preparation, and assay of an antiviral substance from plant cells.
    Gera A; Spiegel S; Loebenstein G
    Methods Enzymol; 1986; 119():729-34. PubMed ID: 3762417
    [No Abstract]   [Full Text] [Related]  

  • 32. Structure--activity relationships for and potentiation of the antimitogenic activity of 2-5A core derived from 2-5A, a mediator of interferon action.
    Torrence PF; Imai J; Lesiak K; Warrinnier J; Balzarini J; De Clercq E
    J Med Chem; 1983 Dec; 26(12):1674-8. PubMed ID: 6196481
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation of lymphocyte mitogenesis by (2'--5') oligo-isoadenylate.
    Kimchi A; Shure H; Revel M
    Nature; 1979 Dec 20-27; 282(5741):849-51. PubMed ID: 514363
    [No Abstract]   [Full Text] [Related]  

  • 34. Principles and background for the construction of transgenic plants displaying multiple virus resistance.
    Truve E; Kelve M; Aaspôllu A; Kuusksalu A; Seppänen P; Saarma M
    Arch Virol Suppl; 1994; 9():41-50. PubMed ID: 8032271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cytokinins on tobacco mosaic virus production in tobacco pith tissue cultures.
    Milo GE; Srivastava BI
    Virology; 1969 Nov; 39(3):621-3. PubMed ID: 5358090
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthesis and breakdown of pppA2'p5'A2'p5'A and transient inhibiton of protein synthesis in extracts from interferon-treated and control cells.
    Williams BR; Kerr IM; Gilbert CS; White CN; Ball LA
    Eur J Biochem; 1978 Dec; 92(2):455-62. PubMed ID: 216547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular events in interferon-treated cells.
    Hovanessian AG
    Differentiation; 1979; 15(3):139-51. PubMed ID: 393560
    [No Abstract]   [Full Text] [Related]  

  • 38. Estimation of the cell-to-cell spread of tobacco mosaic virus infection in mechanically inoculated leaves.
    Dawson WO; Painter PR
    Intervirology; 1978; 9(5):310-5. PubMed ID: 621139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the (2'-5') oligoadenylate system by characterization of cells deficient in their response to interferon.
    Panet A; Arad G; Rappoport S; Hochman Y
    Prog Clin Biol Res; 1985; 202():345-50. PubMed ID: 2421313
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiviral activity of a chemically stabilized 2-5A analog upon microinjection into HeLa cells.
    Defilippi P; Huez G; Verhaegen-Lawalle M; De Clercq E; Imai J; Torrence P; Content J
    FEBS Lett; 1986 Mar; 198(2):326-32. PubMed ID: 2420642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.